The Vision for Tomorrow Foundation is excited to participate in the 2019 John F. Anderson Symposium, “Aniridia, PAX6 and Beyond…” at the University of Virginia on November 2 and 3.  VFT helped to provide financial support of this important meeting...

The Vision for Tomorrow Foundation is proud to support ongoing work with Peter A. Netland, MD, PhD, Vernah Scott Moyston Professor & Chair, Glaucoma Fellowship Program Director and Robert M. Grainger, PhD, Professor of Biology, both at the University of Virginia. They, along with their team, recently performed a retrospective,...

Vision for Tomorrow is proud to partner with the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), to fund a study attempting to identify drugs that will improve vision in people with oculocutaneous albinism (OCA)....

Vision for Tomorrow is proud to partner with the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), to fund a study attempting to identify drugs that will improve vision in people with oculocutaneous albinism (OCA)....

Phase 2 Proof-of-Concept Study for ataluren in Nonsense Mutation Aniridia PTC Therapeutics’ STAR study is a Phase 2 proof-of-concept study of ataluren, an orally administered, first-in-class, protein restoration therapy for the treatment of nonsense mutation aniridia, a rare genetic disorder...

Phase 2 Proof-of-Concept Study for ataluren in Nonsense Mutation Aniridia PTC Therapeutics’ STAR study is a Phase 2 proof-of-concept study of ataluren, an orally administered, first-in-class, protein restoration therapy for the treatment of nonsense mutation aniridia, a rare genetic disorder...